Skip to content
Decision-ready map
• Diligence: sex-disaggregated performance tied to decision thresholds
• Ask for mediator-aware datasets (Hb, pregnancy/life stage) not labels only
• Regulatory durability: alignment with FDA sex-specific evidence guidance
• Update risk: postmarket monitoring for subgroup drift after changes
• Downside control: transparent limitations + safe failure modes
(1) What it is
Sex-based biological differences affecting optical signatures are a diligence-grade risk for threshold-driven products (SpO₂ alerts, NIRS desaturation alarms, spectroscopy-based classifiers). Sex-linked shifts in hemoglobin, skin optical properties, and perfusion can move baseline distributions and widen error tails—creating clinical harm, regulatory delay, reimbursement fragility, and liability exposure. ‘What to validate’ is whether a company can prove and maintain sex-aware performance across updates and settings, not just in pooled pilot results.
(2) Who it helps
This brief is for investors and strategic partners evaluating wearables (PPG/SpO₂), spectroscopy diagnostics, and NIRS/tissue oximetry products for clinical risk, regulatory durability, and defensible claims.
(3) What evidence exists
Mechanistic and empirical signals support the risk. PPG waveform studies show sex-dependent features, implying that algorithmic biomarkers can drift across sexes (Dehghanojamahalleh & Kaya 2019). Large population DRS inversions show sex-associated absorption/scattering, suggesting that calibration priors are not universal (Jonasson et al. 2023). Microcirculation measurements show lower RBC tissue fraction and perfusion in females, which can increase artifacts and change decision reliability (Samils et al. 2023). Quantitative NIRS reports sex differences in baseline oxygenated hemoglobin, emphasizing baseline-sensitive risk (Asahara & Matsukawa 2023). Skin fluorescence varies by sex (Morvová et al. 2018), and Raman serum spectroscopy demonstrates that spectra encode multi-biomarker physiology (Staritzbichler et al. 2021); when biomarkers differ by population, subgroup validation becomes essential. Regulatory expectations also matter: FDA guidance outlines expectations for sex-specific enrollment, analysis, and reporting in device clinical studies, which can affect timelines and claims durability.
(4) Translation barriers
The most common translation failure is pooled reporting: a company shows acceptable mean error but hides worst-group tail risk near thresholds. Additional red flags include absent pregnancy/anemia evidence despite intended use, no plan to capture mediators (Hb), and weak change-control governance for model updates. Evidence can also be device-configuration specific: the ‘validation unit’ must match the commercial BOM and firmware.
(5) Equity/safety checks
Operationalize equity as risk control. Require sex-disaggregated performance distributions and safety metrics, plus documented limitations where evidence is incomplete. Ensure respectful handling of sex vs gender identity in data governance and privacy. Confirm the company has conservative failure modes (quality gating, clinician override) and a postmarket plan to monitor subgroup drift after updates.
(6) Decision questions
• Is there sex-disaggregated evidence tied to decision thresholds (not just pooled accuracy)?
• Are mediators (Hb, life stage) captured so differences are explainable and fixable?
• Does the regulatory plan explicitly align with FDA expectations for sex-specific data?
• What is the update/change-control plan, and how is subgroup drift monitored postmarket?
• Is there a procurement/reimbursement advantage from transparent sex-aware evidence?
(7) Practical next steps
1) Add a ‘sex-aware validity’ section to diligence memos: subgroup metrics, datasets, mediators, and tail-risk near thresholds.
2) Make representative validation (sex + relevant life stages) a financing milestone before scale.
3) Require change control and revalidation triggers after updates; monitor field drift by subgroup.
4) Prefer companies that publish procurement-ready evidence dossiers and transparent limitations.
5) Treat absence of sex-aware evidence as a predictor of regulatory friction and reimbursement weakness.
(8) References
Dehghanojamahalleh S, Kaya M. Sex-Related Differences in Photoplethysmography Signals Measured From Finger and Toe. IEEE J Transl Eng Health Med. 2019;7:1900607.
https://doi.org/10.1109/JTEHM.2019.2938506
Charlton PH, Pilt K, Kyriacou PA. Establishing best practices in photoplethysmography signal acquisition and processing. Physiol Meas. 2022;43(5):050301.
https://doi.org/10.1088/1361-6579/ac6cc4
Jonasson H, Fredriksson I, Bergstrand S, et al. Absorption and reduced scattering coefficients in epidermis and dermis from a Swedish cohort study. J Biomed Opt. 2023;28(11):115001.
https://doi.org/10.1117/1.JBO.28.11.115001
Samils L, Henricson J, Strömberg T, Fredriksson I, Iredahl F. Workload and sex effects in comprehensive assessment of cutaneous microcirculation. Microvasc Res. 2023;148:104547.
https://doi.org/10.1016/j.mvr.2023.104547
Asahara R, Matsukawa K. Prefrontal oxygenation is quantified with time-resolved NIRS: effect of sex on baseline oxygenation and response during exercise. Am J Physiol Regul Integr Comp Physiol. 2023;325:R31–R44.
https://doi.org/10.1152/ajpregu.00048.2023
Morvová M Jr, Jeczko P, Šikurová L. Gender differences in the fluorescence of human skin in young healthy adults. Skin Res Technol. 2018;24(4):599–605.
https://doi.org/10.1111/srt.12471
Hung C-H, Chou T-C, Hsu C-K, Tseng S-H. Broadband absorption and reduced scattering spectra of in-vivo skin using δ-P1 approximation. Biomed Opt Express. 2015;6(2):443–456.
https://doi.org/10.1364/BOE.6.000443
Staritzbichler R, Hunold P, Estrela-Lopis I, et al. Raman spectroscopy on blood serum samples of patients with end-stage liver disease. PLoS One. 2021;16(9):e0256045.
https://doi.org/10.1371/journal.pone.0256045
WHO. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. 2024.
https://www.who.int/publications/i/item/9789240088542
NIH Office of Research on Women’s Health. Sex as a Biological Variable (SABV).
https://orwh.od.nih.gov/sex-as-biological-variable
FDA. Evaluation of Sex-Specific Data in Medical Device Clinical Studies (final guidance). March 2025.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-sex-specific-data-medical-device-clinical-studies-guidance-industry-and-food-and-drug